Photodynamic therapy in Barrett's esophagus:' Results of treatment of 17 patients

Canadian Journal of Gastroenterology

Volumn 20, Issue 4, 2006, Pages 261-264

  Weiss, Alan A ^a   Wiesinger, Holly A R ^a   Owen, David ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adenocarcinoma; Barret's esophagus; Dysplasia; Photodynamic therapy

Indexed keywords

PHOTOFRIN;

ADULT; AGED; ARGON PLASMA COAGULATION; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; ESOPHAGUS SPASM; ESOPHAGUS STRICTURE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PLEURA EFFUSION; PRIORITY JOURNAL; SUNBURN; URTICARIA;

EID: 33646380072     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/954153     Document Type: Article

References (16)

1. Hamilton SR. Pathogenesis of columnar cell lined (Barrett's) esophagus. In: Spechler SJ, Goyal RK, eds. Barrett's Esophagus: Pathophysiology, Diagnosis and Management. New York: Elsevier, 1985:2937.
2. Spechler SJ. Barrett's esophagus and esophageal adenocarcinoma: Pathogenesis, diagnosis, and therapy. Med Clin North Am 2002;86:1423-45.
3. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
4. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
5. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
6. Sampliner RE and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
7. Devesa SS, Blot WJ, Fraumeni J. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
8. National Cancer Institute of Canada: Canadian Cancer Statistics 2004, Canada,
9. Wang KK, Kim JY. Photodynamic therapy in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003;13:483-9.
10. Pass HI. Photodynamic therapy in oncology: Mechanisms and clinical use. J Natl Cancer Inst 1993;85:443-56.
11. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: Long-term results. Gastrointest Endosc 2003;58:183-8.
12. Wolfsen HC, Woodward TA, Raimondo M. Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma. Mayo Clin Proc 2002;77:1176-81.
13. Overholt BF, Panjehpour M. Photodynamic therapy techniques for ablation of Barrett's esophagus. Tech Gastrointest Endosc 2000;2:203-8.
14. Reid BJ, Blount PL, and Rabinovitch PS. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003;13:369-97.
15. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
16. Krishnadath KK, Wang KK, Taniguchi, D, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000;199:624-30.